Rosuvastatin
Rosuvastatin is a potent HMG-CoA reductase inhibitor (statin) with strong LDL-lowering efficacy and cardiovascular outcome data. PED users use it to manage the substantial LDL rise and HDL fall that anabolic steroids — especially oral 17aa compounds — produce. It is one of the more commonly recommended statins in the community because of its potency and relatively favourable interaction profile.
01 Overview
Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, which up-regulates LDL receptors and clears LDL from the circulation. It is among the most potent statins, lowering LDL by roughly 45-55% at moderate doses, and has proven cardiovascular event reduction (e.g. the JUPITER trial).
Because anabolic steroids can drive markedly atherogenic lipid changes, PED users often add a statin during cycles that crash HDL and raise LDL. Rosuvastatin is favoured for its efficacy and because it is less dependent on CYP3A4 metabolism than some statins, reducing certain drug interactions. Muscle symptoms and, rarely, rhabdomyolysis are the main safety concerns, especially relevant in heavily training, high-muscle-mass users where creatine kinase interpretation is complicated.
02 Mechanism
Competitive inhibitor of HMG-CoA reductase, reducing hepatic cholesterol synthesis and up-regulating LDL receptors to clear circulating LDL.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| On-cycle lipid control | 5–20 mg/day | Oral | Titrated to lipid panel; lower doses often adequate for steroid-driven shifts. |
| Hyperlipidaemia (label) | 5–40 mg/day | Oral | Usual 10-20 mg; 40 mg reserved for high-risk patients. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Marked LDL reductionPotent LDL lowering, strongly documented across statin trials. | -45 to -55% | Clinical | |
| Cardiovascular event reductionReduces cardiovascular events in at-risk populations. | outcome data (JUPITER) | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Myalgia / myopathyMuscle aches and weakness; rare progression to myopathy or rhabdomyolysis. | Moderate | Common (myalgia) | Clinical | |
| Transaminase elevationUsually mild, transient rises in liver enzymes. | Mild | Uncommon | Clinical | |
| New-onset hyperglycaemiaSmall increase in risk of raised blood glucose / new diabetes. | Mild | Uncommon | Clinical |